November 17, 2022
BERLIN, Germany — Dr. Dirk Sauer has been named the Chairman of Dopavision’s Advisory Board. Dr. Sauer brings a track record in the development of ophthalmic therapeutics and an industry network to advance MyopiaX, Dopavision’s therapeutic for childhood myopia control. MyopiaX is currently in clinical trials in Germany, Portugal, Spain, and Ireland.
Dr. Sauer is experienced in eye therapeutics development with long-standing global experience in ophthalmology and neuroscience. At Novartis, he successfully led numerous projects and teams during all phases of the drug development process and was, among others, responsible for the development of ophthalmology therapies to treat the wet form of macular degeneration. He also led the company’s Ophthalmology Development Unit as Global Development Unit Head for more than nine years. During that time, he built a development portfolio in various ocular indications, spanning from small molecules to biologics, gene therapies, and digital therapeutics. His leadership included the development unit of the former Alcon Pharma franchise.
“Dirk brings extremely valuable knowledge in both research and product development,” said Mark Wuttke, CEO of Dopavision. “He is familiar with a wealth of indications affecting both back and front of the eye, the selection of the best approaches, and the challenges of bringing them to market. He will be a great addition to our advisory board and will provide leadership for the entire R&D team.”
“I am really excited to chair Dopavision’s Advisory Board,” said Dr. Sauer. “The company has developed an outstanding technology to combat childhood myopia, a very pressing global health problem. I am very happy to contribute to the success of this entirely new concept — a true digital approach to treat eye disease.”